Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies

NCT02151448 is registered in ClinicalTrials.gov with David Bartlett as lead sponsor.

NCT NCT02151448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02151448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies
Lead sponsor
David Bartlett
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2014
Completion date
February 18, 2019
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm of pancreas metastatic to peritoneal surface, malignant peritoneal mesothelioma, peritoneal carcinomatosis